Product Information
VYVANSE 30 MG CHEWABLE TABLET is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $12.3421 per EA under NDC 59417011701. Its NADAC has been published 402 times since Oct 17, 2018.
The High Outlier badge above means this manufacturer's average price in the LISDEXAMFETAMINE DIMESYLATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
30 mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
59417011701
Classification
Brand
Dosage Form
TABLET, CHEWABLE
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
LISDEXAMFETAMINE DIMESYLATEApproval Type
New Drug (NDA)
FDA Application
NDA208510On Market Since
1/28/2017
Pharmacological Classes
Price Statistics
The NADAC for VYVANSE 30 MG CHEWABLE TABLET has been published 402 times since Oct 17, 2018, and over the history we have for it it has risen 31.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.3421 per EA |
|---|---|
| All-time high | $12.4241 (May 15, 2024) |
| All-time low | $9.3782 (Oct 17, 2018) |
| 52-week high | $12.3764 |
| 52-week low | $12.3421 |
| Median price | $11.2652 |
| Average price | $11.2098 |
| Largest weekly change | +5.0% (Jan 12, 2022) |
| Weeks tracked | 402 |
| Tracking since | Oct 17, 2018 |
Generic Alternatives
The matcher finds 3 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 3 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 75% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of VYVANSE 30 MG CHEWABLE TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VYVANSE 30 MG CHEWABLE TABLET, manufactured by Takeda Pharmaceuticals America, Inc., is $12.3421 per EA (NDC 59417011701), effective Jun 24, 2026.
How has the price of VYVANSE 30 MG CHEWABLE TABLET changed over time?
Over the history we have for it, the NADAC for VYVANSE 30 MG CHEWABLE TABLET has risen 31.6%. It has been tracked across 402 weekly CMS publications since Oct 17, 2018.
What are the highest and lowest recorded NADAC prices for VYVANSE 30 MG CHEWABLE TABLET?
Since Oct 17, 2018, the NADAC for VYVANSE 30 MG CHEWABLE TABLET has ranged from a low of $9.3782 (Oct 17, 2018) to a high of $12.4241 (May 15, 2024), with a median of $11.2652 per EA.
Are there cheaper alternatives to VYVANSE 30 MG CHEWABLE TABLET?
Yes. 3 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, LISDEXAMFETAMINE 30 MG CAPSULE, is $3.0366 per EA — about 75% below VYVANSE 30 MG CHEWABLE TABLET.
Who manufactures VYVANSE 30 MG CHEWABLE TABLET?
VYVANSE 30 MG CHEWABLE TABLET (NDC 59417011701) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification